@article{5ee178565db5439c9313a272af382784,
title = "The methodology of surveillance for antimicrobial resistance and healthcare-associated infections in Europe (SUSPIRE): a systematic review of publicly available information",
abstract = "Objectives: Surveillance is a key component of any control strategy for healthcare-associated infections (HAIs) and antimicrobial resistance (AMR), and public availability of methodologic aspects is crucial for the interpretation of the data. We sought to systematically review publicly available information for HAIs and/or AMR surveillance systems organized by public institutions or scientific societies in European countries. Methods: A systematic review of scientific and grey literature following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines was performed. Information on HAIs and/or AMR surveillance systems published until 31 October 2016 were included. Results: A total of 112 surveillance systems were detected; 56 from 20 countries were finally included. Most exclusions were due to lack of publicly available information. Regarding AMR, the most frequent indicator was the proportion of resistant isolates (27 of 34 providing information, 79.42\%); only 18 (52.9\%) included incidence rates; the data were only laboratory based in 33 (78.5\%) of the 42 providing this information. Regarding HAIs in intensive care units, all 22 of the systems providing data included central line–associated bloodstream infections, and 19 (86.3\%) included ventilator-associated pneumonia and catheter-associated urinary tract infections; incidence density was the most frequent indicator. Regarding surgical site infections, the most frequent procedures included were hip prosthesis, colon surgery and caesarean section (21/22, 95.5\%). Conclusions: Publicly available information about the methods and indicators of the surveillance system is frequently lacking. Despite the efforts of European Centre for Disease Control and Prevention (ECDC) and other organizations, wide heterogeneity in procedures and indicators still exists.",
keywords = "Antimicrobial resistance, Epidemiology, Healthcare-associated infections, Surveillance, Systematic review",
author = "\{EPI-Net, Combacte-Magnet and EUCIC Group for SUSPIRE\} and M. N{\'u}{\~n}ez-N{\'u}{\~n}ez and Navarro, \{M. D.\} and V. Palomo and Rajendran, \{N. B.\} and \{del Toro\}, \{M. D.\} and A. Voss and M. Sharland and F. Sifakis and E. Tacconelli and J. Rodr{\'i}guez-Ba{\~n}o and F. Burkert and E. Carrara and \{von Cube\}, M. and L. Drgona and K. Gilchrist and H. Goossens and S. Harbarth and D. Hequet and H. Jafri and G. Kahlmeter and S. Kuster and C. Luxemburger and M. McCarthy and M. Niks and A. Oualim and M. Poljak and O. Sandulescu and A. Schweiger and C. Vuong and I. Wiegand and A. Widmer and Witschi, \{A. T.\} and G. Zanetti and W. Zingg",
note = "Funding Information: Funded by the Innovative Medicines Initiative (IMI), New Drugs for Bad Bugs (ND4BB) programme, European Union's Seventh Framework Programme (FP7/2007-2013) and EFPIA (European Federation of Pharmaceutical Industries and Association) companies' in-kind contribution (IMI 11th) under grant 115737, COMBACTE-MAGNET (Combatting bacterial resistance in Europe—Molecule against Gram negative infections). JRB and MDT receive funding for research from Ministerio de Econom{\'i}a y Competitividad, Instituto de Salud Carlos III, cofinanced by European Regional Development Fund (ERDF) {\textquoteleft}A way to achieve Europe,{\textquoteright} Spanish Network for the Research in Infectious Diseases (REIPI RD12/0015 and REIPI RD16/0016). FS is an employee of AstraZeneca/Medimmune, an EFPIA member company in the IMI JU. Costs related to research contributions by FS are borne by AstraZeneca/Medimmune and are considered to be in-kind contribution under the IMI Joint Undertaking scheme. All other authors declared no conflict of interest related to this systematic review. The funders of the study had no role in study design, data collection, data analysis, data interpretation or manuscript development. This article was seen and approved by all members of the COMBACTE-MAGNET consortia before submission. Publisher Copyright: {\textcopyright} 2017 The Authors",
year = "2018",
month = feb,
doi = "10.1016/j.cmi.2017.07.014",
language = "English",
volume = "24",
pages = "105--109",
journal = "Clinical Microbiology and Infection",
issn = "1198-743X",
publisher = "ELSEVIER SCI LTD",
number = "2",
}